MedPlus Health Services Ltd delivered robust financial results for Q3 FY26, with net profit surging 26.2% year-on-year to ₹57.8 crore compared to ₹45.8 crore in the same period last year. According to reports from CNBC TV18, the pharmacy retail chain demonstrated strong operational efficiency with revenue growing 15.7% YoY to ₹1,806 crore from ₹1,561.4 crore in Q3 FY25. Sequentially, revenue increased 7.5% compared to Q2 FY26, showing consistent growth momentum.
The company's EBITDA increased 19.7% to ₹158.5 crore from ₹132.4 crore in the previous year, while EBITDA margin improved to 8.78% from 8.48% in Q3 FY25. As reported by CNBC TV18, the gross margin stood at ₹472 crore, representing 26.2% and an increase of 110 basis points YoY. The company's private label business also contributed positively, rising 2.6% over the same period last year.
MedPlus continued its aggressive expansion strategy, adding 182 stores during the quarter with 228 gross additions and 116 net additions beyond tier-I cities, bringing the total store count to 5,112 as of December 31, 2025. According to CNBC TV18, stores operational for over 12 months delivered 10.5% revenue growth over Q3 FY25, with a store-level EBITDA margin of 12.4% and operating ROCE at 77.7%.
The company maintained strong operational metrics with pharmacy operating EBITDA of ₹92.5 crore reflecting a 5.2% operating margin, up 10 basis points sequentially. As reported by CNBC TV18, operating cash flow reached ₹90.5 crore, covering 93.5% of operating EBITDA, while the closing cash and bank balance was ₹608 crore. The company's shares ended at ₹798, up by ₹25.70 or 3.33% on the BSE on January 30.
